Please login to the form below

Not currently logged in
Email:
Password:

Gazyva

This page shows the latest Gazyva news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Calquence impresses in previously untreated CLL

AstraZeneca’s Calquence impresses in previously untreated CLL

The impressive data – presented at ASH 2019 – showed that  Calquence (acalabrutinib) combined with Roche’s  Gazyva(obinutuzumab) significantly improved progression-free survival (PFS) when compared to standard chemo-immunotherapy treatment.

Latest news

More from news
Approximately 5 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics